An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2015
At a glance
- Drugs BAY 794620 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jan 2013 Planned End Date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 11 Jan 2012 Planned end date changed from 1 Feb 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov (NCT01028755).